ClinicalTrials.gg
Active, not recruitingNCT04351555NeoADAURAUpdated Sep 9, 2026Results posted

A Study of Osimertinib With or Without Chemotherapy Versus Chemotherapy Alone as Neoadjuvant Therapy for Patients With EGFRm Positive Resectable Non-Small Cell Lung Cancer

A Phase 3 interventional study of Osimertinib and Cisplatin in Non-Small Cell Lung Cancer, sponsored by AstraZeneca. Active, not recruiting at 158 sites in 25 countries. Open to participants aged 18 Years to 100 Years. Per ClinicalTrials.gov, last updated 2026-09-09.

Sponsored by AstraZeneca · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
358
Allocation
Randomized
Ages
18 Years to 100 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 90 studies testing osimertinib in Carcinoma, Non-Small-Cell Lung — 20 open to participants now, 43 under way, 8 of them phase 3. osimertinib · Carcinoma, Non-Small-Cell Lung.

Enrollment
9th of 90
358 · median 51
Started
2020
with 7 others
Phase 3
12 of 90
1 open now
Primary completion
2024-10
later than 8 of 42 live
Registered
53rd of 90
by date
Lead sponsor
29 of 90
AstraZeneca

Among the 90 studies testing osimertinib in Carcinoma, Non-Small-Cell Lung, this one is the 9th largest by enrollment, is one of 8 that started in 2020, is one of 12 in phase 3, reaches primary completion later than 8 of the 42 other live ones, and was the 53rd registered.

Carcinoma, Non-Small-Cell Lung

7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,837 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

20 of the 90 studies testing osimertinib in Carcinoma, Non-Small-Cell Lung are open now, in 7 countries. Recruiting first, the newest first:

15 more — sign in →

By country, each count listing its studies:

All 20 open studies →

About osimertinib

osimertinib: first FDA approval 2015 (TAGRISSO), first EMA approval 2016. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,326 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 225 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years to 100 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 90 studies testing osimertinib in Carcinoma, Non-Small-Cell Lung, or all of them as a file.
02

Study summary

This is a Phase III, randomised, controlled, 3-arm, multi-centre study of neoadjuvant osimertinib as monotherapy or in combination with chemotherapy, versus SoC chemotherapy alone, for the treatment of patients with resectable EGFRm Non-Small Cell Lung Cancer

03

Conditions studied

  • Non-Small Cell Lung Cancer

Keywords

  • Resectable; NSCLC; Osimertinib; EGFRm Positive; Neoadjuvant; Adjuvant
04

Who can participate

Ages eligible
18 Years to 100 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female, at least 18 years of age. For patients aged \<20 years and enrolled in Japan, a written should be obtained from the patient and his or her legally acceptable representative
  • or cytologically documented non-squamous NSCLC with completely resectable (Stage II - IIIB N2) disease (according to Version 8 of the IASLC Cancer Staging Manual [IASLC Staging Manual in Thoracic Oncology 2016]).
  • Complete surgical resection of the primary NSCLC must be deemed achievable, as assessed by a MDT evaluation (which should include a thoracic surgeon, specialised in oncologic procedures).
  • (ECOG) PS of 0 or 1 at enrolment, with no deterioration over the previous 2 weeks prior to baseline or day of first dosing
  • A tumour which harbours one of the 2 common EGFR mutations known to be associated with EGFR-TKI sensitivity (Ex19del, L858R), either alone or in combination with other EGFR mutations (eg., T790M, G719X, Exon20 insertions, S7681 and L861Q).

Exclusion criteria

Exclusion Criteria:

  • Past medical history of ILD, drug-induced ILD, radiation pneumonitis which required treatment, or any evidence of clinically active ILD.
  • History of another primary (including any known or suspected synchronous primary lung cancer), except for the following: Malignancy treated with curative intent and with no known active disease ≥2 years before the first dose of product (IP) and of low potential risk for recurrence; Adequately treated non-melanoma skin cancer or lentigo malignancy without evidence of disease; Adequately treated carcinoma in situ without evidence of disease; Any synchronous Stage IA primary lung cancer that is ≤2 cm and planned to be resected during surgery for the Stage II to IIIB N2 lung tumour.
  • Patients who have pre-operative radiotherapy treatment as part of their care plan
  • Mixed small cell and NSCLC histology
  • Stages I, IIIB N3, IIIC, IVA, and IVB NSCLC
  • T4 tumours infiltrating the great vessels, the carina, the trachea, the oesophagus, the heart, and/or the vertebral body; and/or any bulky N2 disease.
  • Patients who are candidates to undergo only segmentectomies or wedge resections
  • Prior treatment with any systemic anti-cancer therapy for NSCLC including chemotherapy, biologic therapy, immunotherapy, or any investigational drug
  • Prior treatment with EGFR-TKI therapy
  • Current use of (or unable to stop use prior to receiving the first dose of study treatment) medications or herbal supplements known to be strong inducers of cytochrome P450 (CYP) 3A4 (at least 3 weeks prior)
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
358 participants (actual)

Study arms

  • Placebo comparator
    Arm 1: Placebo with platinum-based chemotherapy

    Placebo plus investigator's choice of platinum-based standard of care chemotherapy (pemetrexed/carboplatin or pemetrexed/cisplatin)

    Drug: Cisplatin · Drug: Carboplatin · Drug: Placebo · Drug: Pemetrexed

  • Experimental
    Arm 2: Osimertinib with platinum-based chemotherapy

    Osimertinib 80 mg QD (Dose may be reduced to 40 mg QD at the discretion of the investigator) plus investigator's choice of platinum-based standard of care chemotherapy (pemetrexed/carboplatin or pemetrexed/cisplatin)

    Drug: Osimertinib · Drug: Cisplatin · Drug: Carboplatin · Drug: Pemetrexed

  • Experimental
    Arm 3: Osimertinib monotherapy

    Osimertinib 80 mg QD (Dose may be reduced to 40 mg QD at the discretion of the investigator)

    Drug: Osimertinib

Interventions

  • Oral

    Also known as: AZD9291; TAGRISSO

  • Cisplatin (75mg/m2) to be administered with pemetrexed on Day 1 of every 3-week cycle for 3 cycles.

  • Carboplatin (AUC5) to be administered with pemetrexed on Day 1 of every 3-week cycle for 3 cycles

  • DrugPlacebo

    Oral

  • Pemetrexed (500 mg/m2) to be administered with cisplatin or carboplatin on Day 1 of every 3-week cycle for 3 cycles

06

What researchers measure

Primary outcomes

  1. Major Pathological Response (MPR) - IASLC Method

    Defined as ≤10% viable cancer cells in the surgical specimen, as assessed per central pathology laboratory post-surgery (IASLC method). Patients will only be considered to have an MPR if they also have an R0 margin result.

    Time frame: From date of randomization to an average of 12 weeks after the first dose

  2. Major Pathological Response (MPR) - Chemotherapy Method

    Defined as ≤10% viable cancer cells in the surgical specimen, as assessed per central pathology laboratory post-surgery (chemotherapy method). Patients will only be considered to have an MPR if they also have an R0 margin result.

    Time frame: From date of randomization to an average of 12 weeks after the first dose

Secondary outcomes

  1. Pathological Complete Response (pCR) - IASLC Method

    Defined as absence of any viable cancer cells in the dissected tumour samples, including the main tumour, lymph nodes, and margins as assessed per central pathology laboratory post-surgery using IASLC method. Patients will only be considered to have pCR if they also have an R0 margin result based on site assessment.

    Time frame: From date of randomization to an average of 12 weeks after the first dose

  2. Pathological Complete Response (pCR) - Chemotherapy Method

    Defined as absence of any viable cancer cells in the dissected tumour samples, including the main tumour, lymph nodes, and margins as assessed per central pathology laboratory post-surgery using chemotherapy method. Patients will only be considered to have pCR if they also have an R0 margin result based on site assessment.

    Time frame: From date of randomization to an average of 12 weeks after the first dose

  3. Downstaging

    Measured using pathologic mediastinal lymph node evaluation. Pathological downstaging is defined as baseline N2 patients becoming N1/N0 or N1 to N0 at the time of surgery. Only patients with pathological staging at both baseline and surgery are included in this analysis.

    Time frame: From date of randomization to an average of 12 weeks after the first dose.

  4. Concordance of EGFRm Status Between Tumor Tissue DNA and Patient-matched Plasma-derived ctDNA (Mutation Ex19Del or L858R)

    Comparing the baseline central cobas® EGFR Mutation Test V2 between tumor tissue DNA and matched plasma ctDNA results (excluding invalid results). Since this endpoint uses pre-randomization data, treatment arms were combined for the analysis.

    Time frame: Screening/Baseline

  5. Concordance of EGFR Mutation Status Between the Local and Central Test Results From Baseline Tumor Samples (Mutation Ex19Del or L858R)

    Comparing the local EGFR mutation test result used for patient selection with the retrospective baseline central cobas® EGFR Mutation Test V2 results (excluding invalid results). Since this endpoint uses pre-randomization data, treatment arms were combined for the analysis.

    Time frame: Screening/Baseline

  6. Change From Baseline in EORTC QLQ-C30 Primary Subscale Scores (Neoadjuvant Period)

    Average change from baseline across all visits are reported. The analysis was performed using a MMRM analysis on the change from baseline in the score at each visit, including subject (random effect), treatment, visit (fixed effect \& repeated measure) and treatment by visit interaction as explanatory variables, with the baseline score as a covariate along with the baseline score by assessment interaction. EORTC QLQ-C30 has 30 questions and questions are combined to produce symptom scales, individual symptom items, functional scales, and global health status (GHS)/quality of life (QoL). Each of the scale/items range from 0-100 after a linear transformation. Positive change from baseline scores on the GHS/QoL and functioning scales indicate improvement on health status/function, and negative change scores on symptom scales/items represent less symptom severity/improvement on symptom status.

    Time frame: Assessed at baseline, Cycle 2 Day1, Cycle 3 Day1, and Pre-surgical assessment (on D64, -1 to +21 days ).

  7. Change From Baseline in EORTC QLQ-LC13 Primary Subscale Scores (Neoadjuvant Period)

    Average change from baseline across all visits are reported. The analysis was performed using a MMRM analysis on the change from baseline in the score at each visit, including subject (as a random effect), treatment, visit (as fixed effect and repeated measure) and treatment by visit interaction as explanatory variables, with the baseline score as a covariate along with the baseline score by assessment interaction. EORTC QLQ-LC13 has 13 questions and scores range from 0-100 after a linear transformation. Questions assess cough, hemoptysis, dyspnea, site specific pain, sore mouth, dysphagia, peripheral neuropathy, and alopecia and pain medication. While the QLQ-LC13 includes more scales, only the Coughing, Pain in chest, and Dyspnea subscale scores were analyzed for this endpoint. Negative change from baseline scores indicates less symptom severity, and thus improvement on health status.

    Time frame: Assessed at baseline, Cycle 2 Day1, Cycle 3 Day1, and Pre-surgical assessment (on D64, -1 to +21 days).

  8. PK Plasma Concentrations of Osimertinib

    Summary of plasma concentrations (nM) of Osimertinib

    Time frame: From the pre-dose of Cycle 2 to post-dose of Cycle 3 (each cycle is 21 days)

  9. PK Plasma Concentrations of AZ5104

    Summary of plasma concentrations (nM) of AZ5104

    Time frame: From the pre-dose of Cycle 2 to post-dose of Cycle 3 (each cycle is 21 days)

07

Results

Posted Jun 5, 2026

Participant flow

This Phase III, randomized, controlled, 3-arm, multi-center study was conducted in patients with resectable EGFRm NSCLC. A total of 1044 participants were screened between 16DEC2020 and 08DEC2023. 358 were randomized in a 1:1:1 ratio to 3 study arms. 2 participants were randomized to Osi + Chemo arm but did not receive any treatment (2 withdrawn).

Participant flow — Overall Study
MilestoneOsimertinib + ChemoOsimertinibPlacebo + Chemo
Started121117120
Subject received any study treatment119117120
Subjects ongoing neoadjuvant treatment000
Subjects completed neoadjuvant treatment107115111
Completed000
Not completed121117120
Withdrew: Death377
Withdrew: Study ongoing115109110
Withdrew: Withdrawal by subject213
Withdrew: No reason is provided.100

Outcome measures

PrimaryMajor Pathological Response (MPR) - IASLC Method

Defined as ≤10% viable cancer cells in the surgical specimen, as assessed per central pathology laboratory post-surgery (IASLC method). Patients will only be considered to have an MPR if they also have an R0 margin result.

Time frame:
From date of randomization to an average of 12 weeks after the first dose
Reported as:
Number · Percentage of Participants
Major Pathological Response (MPR) - IASLC Method
Percentage of ParticipantsOsimertinib + ChemoOsimertinibPlacebo + Chemo
Major Pathological Response (MPR) - IASLC Method25.6 (18.1 to 34.4)24.8 (17.3 to 33.6)1.7 (0.2 to 5.9)
Statistical analysis
  • Osimertinib + Chemo vs Placebo + Chemo · Cochran-Mantel-Haenszel · p = <0.0001 · Odds ratio (or): 19.82 · 95% CI 4.60 to 85.32(Osi + Chemo) vs. (Placebo + Chemo)
  • Osimertinib vs Placebo + Chemo · Cochran-Mantel-Haenszel · p = <0.0001 · Odds ratio (or): 19.28 · 95% CI 4.56 to 81.63Osi vs. (Placebo+Chemo)
PrimaryMajor Pathological Response (MPR) - Chemotherapy Method

Defined as ≤10% viable cancer cells in the surgical specimen, as assessed per central pathology laboratory post-surgery (chemotherapy method). Patients will only be considered to have an MPR if they also have an R0 margin result.

Time frame:
From date of randomization to an average of 12 weeks after the first dose
Reported as:
Number · Percentage of Participants
Major Pathological Response (MPR) - Chemotherapy Method
Percentage of ParticipantsOsimertinib + ChemoOsimertinibPlacebo + Chemo
Major Pathological Response (MPR) - Chemotherapy Method24.8 (17.4 to 33.5)20.5 (13.6 to 29.0)1.7 (0.2 to 5.9)
Statistical analysis
  • Osimertinib + Chemo vs Placebo + Chemo · Cochran-Mantel-Haenszel · p = <0.0001 · Odds ratio (or): 19.17 · 95% CI 4.45 to 82.66(Osi + Chemo) vs. (Placebo + Chemo)
  • Osimertinib vs Placebo + Chemo · Cochran-Mantel-Haenszel · p = <0.0001 · Odds ratio (or): 14.68 · 95% CI 3.46 to 62.28Osi vs. (Placebo+Chemo)
SecondaryPathological Complete Response (pCR) - IASLC Method

Defined as absence of any viable cancer cells in the dissected tumour samples, including the main tumour, lymph nodes, and margins as assessed per central pathology laboratory post-surgery using IASLC method. Patients will only be considered to have pCR if they also have an R0 margin result based on site assessment.

Time frame:
From date of randomization to an average of 12 weeks after the first dose
Reported as:
Number · Percentage of Participants
Pathological Complete Response (pCR) - IASLC Method
Percentage of ParticipantsOsimertinib + ChemoOsimertinibPlacebo + Chemo
Pathological Complete Response (pCR) - IASLC Method4.1 (1.4 to 9.4)8.5 (4.2 to 15.2)0 (0.0 to 3.0)
Statistical analysis
  • Osimertinib + Chemo vs Placebo + Chemo · Fisher Exact · p = 0.0599 (P-values are obtained from the Fisher exact test as CMH is not calculable.)
  • Osimertinib vs Placebo + Chemo · Fisher Exact · p = 0.0007 (P-values are obtained from the Fisher exact test as CMH is not calculable.)
SecondaryPathological Complete Response (pCR) - Chemotherapy Method

Defined as absence of any viable cancer cells in the dissected tumour samples, including the main tumour, lymph nodes, and margins as assessed per central pathology laboratory post-surgery using chemotherapy method. Patients will only be considered to have pCR if they also have an R0 margin result based on site assessment.

Time frame:
From date of randomization to an average of 12 weeks after the first dose
Reported as:
Number · Percentage of Participants
Pathological Complete Response (pCR) - Chemotherapy Method
Percentage of ParticipantsOsimertinib + ChemoOsimertinibPlacebo + Chemo
Pathological Complete Response (pCR) - Chemotherapy Method4.1 (1.4 to 9.4)8.5 (4.2 to 15.2)0 (0.0 to 3.0)
Statistical analysis
  • Osimertinib + Chemo vs Placebo + Chemo · Fisher Exact · p = 0.0599 (P-values are obtained from the Fisher exact test as CMH is not calculable.)
  • Osimertinib vs Placebo + Chemo · Fisher Exact · p = 0.0007 (P-values are obtained from the Fisher exact test as CMH is not calculable.)
SecondaryDownstaging

Measured using pathologic mediastinal lymph node evaluation. Pathological downstaging is defined as baseline N2 patients becoming N1/N0 or N1 to N0 at the time of surgery. Only patients with pathological staging at both baseline and surgery are included in this analysis.

Time frame:
From date of randomization to an average of 12 weeks after the first dose.
Reported as:
Count of participants · Participants
Downstaging
ParticipantsOsimertinib + ChemoOsimertinibPlacebo + Chemo
Baseline staging N1 or N2504829
Baseline staging N1252822
Baseline staging N225207
Statistical analysis
  • Osimertinib + Chemo vs Placebo + Chemo · Cochran-Mantel-Haenszel · p = 0.0064 (Cochran-Mantel-Haenszel test stratified by disease stage, race, and mutation type.) · Odds ratio (or): 2.36 · 95% CI 1.24 to 4.47(Osimertinib + Chemo) vs. (Placebo + Chemo)
  • Osimertinib vs Placebo + Chemo · Cochran-Mantel-Haenszel · p = 0.0148 · Odds ratio (or): 2.19 · 95% CI 1.15 to 4.16Osimertinib vs. (Placebo + Chemo)
  • Osimertinib + Chemo vs Placebo + Chemo · Cochran-Mantel-Haenszel · p = 0.2188 · Odds ratio (or): 1.73 · 95% CI 0.69 to 4.30(Osimertinib + Chemo) vs. (Placebo + Chemo)
  • Osimertinib vs Placebo + Chemo · Cochran-Mantel-Haenszel · p = 0.4921 · Odds ratio (or): 1.34 · 95% CI 0.57 to 3.19Osimertinib vs. (Placebo + Chemo)
  • Osimertinib + Chemo vs Placebo + Chemo · Cochran-Mantel-Haenszel · p = 0.0031 · Odds ratio (or): 4.77 · 95% CI 1.62 to 14.00(Osimertinib + Chemo) vs. (Placebo + Chemo)
  • Osimertinib vs Placebo + Chemo · Cochran-Mantel-Haenszel · p = 0.0075 · Odds ratio (or): 4.18 · 95% CI 1.44 to 12.14Osimertinib vs. (Placebo + Chemo)
SecondaryConcordance of EGFRm Status Between Tumor Tissue DNA and Patient-matched Plasma-derived ctDNA (Mutation Ex19Del or L858R)

Comparing the baseline central cobas® EGFR Mutation Test V2 between tumor tissue DNA and matched plasma ctDNA results (excluding invalid results). Since this endpoint uses pre-randomization data, treatment arms were combined for the analysis.

Time frame:
Screening/Baseline
Reported as:
Count of participants · Participants
Concordance of EGFRm Status Between Tumor Tissue DNA and Patient-matched Plasma-derived ctDNA (Mutation Ex19Del or L858R)
ParticipantsPositiveNegative
Plasma ctDNA positive1273
Plasma ctDNA negative253101
SecondaryConcordance of EGFR Mutation Status Between the Local and Central Test Results From Baseline Tumor Samples (Mutation Ex19Del or L858R)

Comparing the local EGFR mutation test result used for patient selection with the retrospective baseline central cobas® EGFR Mutation Test V2 results (excluding invalid results). Since this endpoint uses pre-randomization data, treatment arms were combined for the analysis.

Time frame:
Screening/Baseline
Reported as:
Count of participants · Participants
Concordance of EGFR Mutation Status Between the Local and Central Test Results From Baseline Tumor Samples (Mutation Ex19Del or L858R)
ParticipantsPositiveNegative
Local results positive1777
Local results negative08
SecondaryChange From Baseline in EORTC QLQ-C30 Primary Subscale Scores (Neoadjuvant Period)

Average change from baseline across all visits are reported. The analysis was performed using a MMRM analysis on the change from baseline in the score at each visit, including subject (random effect), treatment, visit (fixed effect \& repeated measure) and treatment by visit interaction as explanatory variables, with the baseline score as a covariate along with the baseline score by assessment interaction. EORTC QLQ-C30 has 30 questions and questions are combined to produce symptom scales, individual symptom items, functional scales, and global health status (GHS)/quality of life (QoL). Each of the scale/items range from 0-100 after a linear transformation. Positive change from baseline scores on the GHS/QoL and functioning scales indicate improvement on health status/function, and negative change scores on symptom scales/items represent less symptom severity/improvement on symptom status.

Time frame:
Assessed at baseline, Cycle 2 Day1, Cycle 3 Day1, and Pre-surgical assessment (on D64, -1 to +21 days ).
Reported as:
Least squares mean · Score
Change From Baseline in EORTC QLQ-C30 Primary Subscale Scores (Neoadjuvant Period)
ScoreOsimertinib + ChemoOsimertinibPlacebo + Chemo
Functional Scale: Physical Functioning Score (Average change from Baseline)-1.21 (-3.09 to 0.67)1.34 (-0.57 to 3.25)-1.70 (-3.57 to 0.17)
Symptom Scale: Fatigue Score (Average change from Baseline)8.62 (5.81 to 11.42)2.64 (-0.21 to 5.49)5.95 (3.16 to 8.75)
Individual Symptom Item: Appetite Loss Score (Average change from Baseline)15.82 (12.35 to 19.29)9.44 (5.93 to 12.95)5.92 (2.47 to 9.38)
Global Health Status/ Quality of Life Score (Average change from Baseline)-2.55 (-5.01 to -0.09)-1.32 (-3.80 to 1.17)-2.01 (-4.45 to 0.44)
SecondaryChange From Baseline in EORTC QLQ-LC13 Primary Subscale Scores (Neoadjuvant Period)

Average change from baseline across all visits are reported. The analysis was performed using a MMRM analysis on the change from baseline in the score at each visit, including subject (as a random effect), treatment, visit (as fixed effect and repeated measure) and treatment by visit interaction as explanatory variables, with the baseline score as a covariate along with the baseline score by assessment interaction. EORTC QLQ-LC13 has 13 questions and scores range from 0-100 after a linear transformation. Questions assess cough, hemoptysis, dyspnea, site specific pain, sore mouth, dysphagia, peripheral neuropathy, and alopecia and pain medication. While the QLQ-LC13 includes more scales, only the Coughing, Pain in chest, and Dyspnea subscale scores were analyzed for this endpoint. Negative change from baseline scores indicates less symptom severity, and thus improvement on health status.

Time frame:
Assessed at baseline, Cycle 2 Day1, Cycle 3 Day1, and Pre-surgical assessment (on D64, -1 to +21 days).
Reported as:
Least squares mean · Score
Change From Baseline in EORTC QLQ-LC13 Primary Subscale Scores (Neoadjuvant Period)
ScoreOsimertinib + ChemoOsimertinibPlacebo + Chemo
Coughing Score (Average change from Baseline)-8.69 (-11.59 to -5.79)-6.09 (-9.01 to -3.17)-6.87 (-9.78 to -3.96)
Pain in Chest Score (Average change from Baseline)0.17 (-2.07 to 2.40)-1.49 (-3.76 to 0.77)0.30 (-1.93 to 2.54)
Dyspnea Score (Average change from Baseline)1.16 (-0.87 to 3.18)0.73 (-1.31 to 2.78)0.84 (-1.19 to 2.87)
SecondaryPK Plasma Concentrations of Osimertinib

Summary of plasma concentrations (nM) of Osimertinib

Time frame:
From the pre-dose of Cycle 2 to post-dose of Cycle 3 (each cycle is 21 days)
Reported as:
Geometric mean · nM
PK Plasma Concentrations of Osimertinib
nMOsimertinib + ChemoOsimertinib
Cycle2 Day1 - Predose333.1 ± 70.82415.9 ± 55.7
Cycle 2 Day 1 - Post-dose340.8 ± 74.11406.6 ± 64.86
Cycle 3 Day 1 - Predose300 ± 58.85345.3 ± 47.63
Cycle 3 Day 1 - Post-dose294.7 ± 62357.3 ± 48.77
SecondaryPK Plasma Concentrations of AZ5104

Summary of plasma concentrations (nM) of AZ5104

Time frame:
From the pre-dose of Cycle 2 to post-dose of Cycle 3 (each cycle is 21 days)
Reported as:
Geometric mean · nM
PK Plasma Concentrations of AZ5104
nMOsimertinib + ChemoOsimertinib
Cycle2 Day1 - Predose45.08 ± 75.4549.24 ± 68.01
Cycle 2 Day 1 - Post-dose45.31 ± 73.5648.46 ± 69.71
Cycle 3 Day 1 - Predose40.52 ± 55.4442.72 ± 47.87
Cycle 3 Day 1 - Post-dose39.32 ± 58.4742.86 ± 49.32

Adverse events

Collected over Includes adverse events during the neoadjuvant analysis period, defined as from the first dose to the minimum of (date of last dose in neoadjuvant period + 28 days, the next treatment start date - 1, date of withdrawal of consent, date of death). For participants who received Osimertinib or Placebo, this was up to 138 days. For participants who received Pemetrexed, Cisplatin or Carboplatin, this was up to 107 days.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Osimertinib + Chemo3/121 (2.5%)24/119 (20.2%)106/119 (89.1%)
Osimertinib7/117 (6%)13/117 (11.1%)88/117 (75.2%)
Placebo + Chemo7/120 (5.8%)24/120 (20%)101/120 (84.2%)
Most frequent serious events
Showing 10 of 51
Most frequent serious events
EventOsimertinib + ChemoOsimertinibPlacebo + Chemo
PneumoniaInfections and infestations2/1193/1174/120
Pulmonary embolismRespiratory, thoracic and mediastinal disorders2/1192/1170/120
COVID-19Infections and infestations2/1190/1171/120
Rash maculo-papularSkin and subcutaneous tissue disorders2/1190/1170/120
EmbolismVascular disorders1/1190/1172/120
ColitisGastrointestinal disorders0/1190/1172/120
Wound infectionInfections and infestations0/1191/1170/120
Coronary artery diseaseCardiac disorders0/1191/1170/120
Diabetes mellitusMetabolism and nutrition disorders0/1191/1170/120
HyponatraemiaMetabolism and nutrition disorders1/1191/1170/120
Most frequent other events
Showing 10 of 33
Most frequent other events
EventOsimertinib + ChemoOsimertinibPlacebo + Chemo
ConstipationGastrointestinal disorders32/11917/11741/120
NauseaGastrointestinal disorders33/1198/11729/120
DiarrhoeaGastrointestinal disorders29/11931/11712/120
Neutrophil count decreasedInvestigations30/1192/11722/120
RashSkin and subcutaneous tissue disorders28/11915/1179/120
Decreased appetiteMetabolism and nutrition disorders24/1197/11722/120
Platelet count decreasedInvestigations23/1195/1173/120
AnaemiaBlood and lymphatic system disorders22/1196/11722/120
StomatitisGastrointestinal disorders22/11910/11712/120
CoughRespiratory, thoracic and mediastinal disorders13/11916/11719/120

Baseline characteristics

Full Analysis Set (All randomized participants, regardless of the treatment actually received)

Age, Continuous
Age, Continuous(years)Osimertinib + ChemoOsimertinibPlacebo + ChemoTotal
Mean63.7 ± 9.8364.8 ± 9.6963.9 ± 9.6664.1 ± 9.71
Age, Customized
Age, Customized(Participants)Osimertinib + ChemoOsimertinibPlacebo + ChemoTotal
<50 years11101132
>=50 and <65 years514148140
>=65 and <75 years414948138
>=75 years18171348
Sex: Female, Male
Sex: Female, Male(Participants)Osimertinib + ChemoOsimertinibPlacebo + ChemoTotal
Female727690238
Male494130120
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Osimertinib + ChemoOsimertinibPlacebo + ChemoTotal
Asian878890265
White29272985
Other5106
Not reported0112
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Osimertinib + ChemoOsimertinibPlacebo + ChemoTotal
Hispanic or Latino76821
Not Hispanic or Latino114111111336
Not reported0011
08

Study locations

158 sites
  • Research Site
    Duarte, California 91010, United States
  • Research Site
    Irvine, California 92618, United States
  • Research Site
    San Francisco, California 94143, United States
  • Research Site
    Santa Monica, California 90404, United States
  • Research Site
    Santa Rosa, California 95403, United States
  • Research Site
    Boston, Massachusetts 02215, United States
  • Research Site
    Lebanon, New Hampshire 03756, United States
  • Research Site
    Commack, New York 11725, United States
  • Research Site
    New York, New York 10032, United States
  • Research Site
    Houston, Texas 77030, United States
  • Research Site
    Fairfax, Virginia 22031, United States
  • Research Site
    Seattle, Washington 98104, United States
  • Research Site
    Graz, 8036, Austria
  • Research Site
    Vienna, 1210, Austria
  • Research Site
    Barretos, 14784-400, Brazil
  • Research Site
    Fortaleza, 60135-040, Brazil
  • Research Site
    Jaú, 17204310, Brazil
  • Research Site
    Porto Alegre, 90035-000, Brazil
  • Research Site
    Porto Alegre, 90610-000, Brazil
  • Research Site
    Recife, 52010-075, Brazil
  • Research Site
    Rio de Janeiro, 22271-110, Brazil
  • Research Site
    Santa Maria, 97015-450, Brazil
  • Research Site
    São José do Rio Preto, 15090-000, Brazil
  • Research Site
    São Paulo, 01327-001, Brazil
  • Research Site
    São Paulo, 04038-034, Brazil
  • Research Site
    São Paulo, 04501-000, Brazil
  • Research Site
    Panagyurishte, 4500, Bulgaria
  • Research Site
    Pleven, 5804, Bulgaria
  • Research Site
    Sofia, 1113, Bulgaria
  • Research Site
    Toronto, Ontario M5G 2N2, Canada
  • Research Site
    Montreal, Quebec H4A 3J1, Canada
  • Research Site
    Las Condes, 7560908, Chile
  • Research Site
    Santiago, 7500713, Chile
  • Research Site
    Santiago, 7500921, Chile
  • Research Site
    Beijing, 100142, China
  • Research Site
    Beijing, 100191, China
  • Research Site
    Beijing, CN-100730, China
  • Research Site
    Changsha, 410008, China
  • Research Site
    Changsha, 410013, China
  • Research Site
    Chengdu, 610041, China
  • Research Site
    Chongqing, 400037, China
  • Research Site
    Guangzhou, 510062, China
  • Research Site
    Guangzhou, 510095, China
  • Research Site
    Guangzhou, 510120, China
  • Research Site
    Guangzhou, 510515, China
  • Research Site
    Hangzhou, 310009, China
  • Research Site
    Hangzhou, 310022, China
  • Research Site
    Kunming, 650118, China
  • Research Site
    Nanchang, 330006, China
  • Research Site
    Nantong, 226001, China
  • Research Site
    Shandong, China
  • Research Site
    Shanghai, 200030, China
  • Research Site
    Shanghai, 200032, China
  • Research Site
    Shanghai, 200433, China
  • Research Site
    Suzhou, 215006, China
  • Research Site
    Ürümqi, 830000, China
  • Research Site
    Wanzhou, 404000, China
  • Research Site
    Wenzhou, CN-325000, China
  • Research Site
    Xiamen, 361004, China
  • Research Site
    Yangzhou, 225001, China
  • Research Site
    Avignon, 84902, France
  • Research Site
    Bordeaux, 33000, France
  • Research Site
    Berlin, 12351, Germany
  • Research Site
    Bielefeld, 33611, Germany
  • Research Site
    Cologne, 51109, Germany
  • Research Site
    Esslingen a.N., 73730, Germany
  • Research Site
    Freiburg im Breisgau, 79106, Germany
  • Research Site
    Gauting, 82131, Germany
  • Research Site
    Georgsmarienhütte, 49124, Germany
  • Research Site
    Halle, 06120, Germany
  • Research Site
    Oldenburg, 26121, Germany
  • Research Site
    Würzburg, 97067, Germany
  • Research Site
    Mumbai, 400012, India
  • Research Site
    Namakkal, 637001, India
  • Research Site
    New Delhi, 110029, India
  • Research Site
    Varanasi, 221005, India
  • Research Site
    Haifa, 3109601, Israel
  • Research Site
    Jerusalem, 91120, Israel
  • Research Site
    Kfar Saba, 95847, Israel
  • Research Site
    Petah Tikva, 49100, Israel
  • Research Site
    Ramat Gan, 5265601, Israel
  • Research Site
    Tel Aviv, 62748, Israel
  • Research Site
    Bari, 70124, Italy
  • Research Site
    Florence, 50134, Italy
  • Research Site
    Monza, 20900, Italy
  • Research Site
    Orbassano, 10043, Italy
  • Research Site
    Padova, 35128, Italy
  • Research Site
    Rozzano, 20089, Italy
  • Research Site
    Varese, 21100, Italy
  • Research Site
    Akashi-shi, 673-8558, Japan
  • Research Site
    Bunkyō City, 113-8431, Japan
  • Research Site
    Chiba, 260-8677, Japan
  • Research Site
    Hiroshima, 734-8551, Japan
  • Research Site
    Kashiwa, 227-8577, Japan
  • Research Site
    Kōtoku, 135-8550, Japan
  • Research Site
    Kyoto, 606-8507, Japan
  • Research Site
    Niigata, 951-8566, Japan
  • Research Site
    Osaka, 541-8567, Japan
  • Research Site
    Sakai, 590-0197, Japan
  • Research Site
    Sakaishi, 591-8555, Japan

Showing the first 100 of 158 sites across 25 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • He J, Tsuboi M, Weder W, Chen KN, Hochmair MJ, Shih JY, Lee SY, Lee KY, Nhung NV, Saeteng S, Liu L, Xing L, Gia NH, Murakami S, Han Y, Saavedra MP, Yoon SH, Teixeira CHA, Escriu C, Martinez-Marti A, Blakely CM, Yatabe Y, Dacic S, Rukazenkov Y, Huang X, Dayal A, Chaft JE; NeoADAURA Investigators. Neoadjuvant Osimertinib for Resectable EGFR-Mutated Non-Small Cell Lung Cancer. J Clin Oncol. 2025 Sep 10;43(26):2875-2887. doi: 10.1200/JCO-25-00883. Epub 2025 Jun 2. PubMed 40454705 ↗
  • Murat-Onana ML, Ramalingam SS, Janne PA, Gray JE, Ahn MJ, John T, Yatabe Y, Huang X, Rukazenkov Y, Javey M, Brown H, Li-Sucholeiki X. EGFR mutation testing across the osimertinib clinical program. Lung Cancer. 2025 Jun;204:108549. doi: 10.1016/j.lungcan.2025.108549. Epub 2025 Apr 18. PubMed 40311309 ↗
  • Lee JB, Choi SJ, Shim HS, Park BJ, Lee CY, Sudhaman S, Velichko S, Hong MH, Cho BC, Lim SM. Neoadjuvant and Adjuvant Osimertinib in Stage IA to IIIA, EGFR-Mutant NSCLC (NORA). J Thorac Oncol. 2025 May;20(5):641-650. doi: 10.1016/j.jtho.2024.12.023. Epub 2024 Dec 26. PubMed 39732365 ↗
  • Tsuboi M, Weder W, Escriu C, Blakely C, He J, Dacic S, Yatabe Y, Zeng L, Walding A, Chaft JE. Neoadjuvant osimertinib with/without chemotherapy versus chemotherapy alone for EGFR-mutated resectable non-small-cell lung cancer: NeoADAURA. Future Oncol. 2021 Nov;17(31):4045-4055. doi: 10.2217/fon-2021-0549. Epub 2021 Jul 19. PubMed 34278827 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Supporting information: Study protocol, Statistical analysis plan

Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Access criteria: When a request has been approved AstraZeneca will provide access to the de-identified individual patient-level data in an approved sponsored tool. Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Data sharing details ↗ · astrazenecagroup-dt.pharmacm.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2020 to primary completion in Oct 2024, 45 months.

Results were first posted in Jun 2026, 1 year 7 months after primary completion.

Of 315 industry-sponsored phase 3 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 27 and three quarters within 57. This study's 45 months is above that.

Counting every sponsor, half of 424 studies reached it within 45 months; a quarter within 30 and three quarters within 69.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 1, 2020
First posted
Apr 17, 2020
StartActual
Dec 16, 2020
Primary completionActual
Oct 15, 2024
CompletionEst.
Jun 13, 2029
Results first posted
Jun 5, 2026
Last update
Sep 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 9, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04351555
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
Apr 17, 2020
Start date
Dec 16, 2020
Primary completion
Oct 15, 2024
Completion
Jun 13, 2029 (estimated)
Results posted
Jun 5, 2026
Last update
Sep 9, 2026

Study contacts

Jamie Chaft, MD
principal investigator · Memorial Sloan Kettering, USA
keiju Aokage, MD
principal investigator · National Cancer Center Hospital East, Japan
Walter Weder, MD
principal investigator · Thoraxchirurgie Bethanien, Switzerland

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Osimertinib · Cisplatin · Carboplatin · Pemetrexed

Start the discussion